| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03594175 2019-002124-32 Details | 2023-08-09 Interventional | 3 | 462 | Reteplase Tissue Plasmino… Thrombosis Catheter Occlus… | Due to ongoing recruitment challenges globally, it is not possible to complete this study. The
decision is not based on any reported changes in the safety profile or any concerns with the
anticipated efficacy profile of the investigational product. - | |||
| NCT02792413 Details | 2023-08-09 Interventional | 4 | 4 | Denosumab Kidney Diseases Osteoporosis Renal Insuffici… Female With Ost… | Modified study and new deposit in RECHMPL21_0451 - | |||
| NCT05758818 Details | 2023-08-08 Interventional | 1 | 6 | Moxifloxacin Cardiac Repolar… | sponsor decision - | |||
| NCT05222516 Details | 2023-08-08 Interventional | 2 | 63 | Broncho-Vaxom Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | Recommendation of DSMB (futility of Endpoints) - | |||
| NCT04398368 Details | 2023-08-08 Interventional | 2 | 25 | Gemcitabine Kidney Neoplasm… Pelvic Neoplasm… Ureteral Neopla… Stage 0a Renal … Stage 0a Renal … Stage 0a Ureter… Stage 0is Renal… Stage 0is Renal… Stage 0is Urete… Stage I Renal P… Stage I Renal P… Stage I Ureter … Stage II Renal … Stage II Renal … Stage II Ureter… Stage III Renal… Stage III Renal… Stage III Urete… Stage IV Renal … Stage IV Renal … Stage IV Ureter… | Focus research efforts on other projects. Study target enrollment was anticipated for 90 participants but only 23 participants completed treatment before study was terminated. The study was terminated due to insufficient resources and funding to support continuation of the trial. PI decision to terminate. | |||
| NCT04224688 2019-003451-11 Details | 2023-08-08 Interventional | 3 | 30 | Rozanolixizumab Purpura, Thromb… Thrombocytopeni… Primary Immune … | Strategic Business Decision; Not a safety decision - | |||
| NCT04204122 Details | 2023-08-08 Interventional | 2 | 0 | Moxifloxacin Graft vs Host D… Ocular Graft-ve… | Investigator decided to close study - | |||
| NCT04200456 2019-000884-26 Details | 2023-08-08 Interventional | 3 | 33 | Rozanolixizumab Purpura, Thromb… Thrombocytopeni… Primary Immune … | Strategic Business Decision; Not a safety decision - | |||
| NCT03330457 Details | 2023-08-08 Interventional | 2 | 18 | Betrixaban Bleeding | Ended prematurely - | |||
| NCT05399550 Details | 2023-08-07 Interventional | 2 | 0 | Balovaptan Cerebral Infarc… Ischemia Ischemic Stroke Stroke Acute Ischemic … | Sponsor's decision - | |||
| NCT04969991 Details | 2023-08-07 Interventional | 2 | 18 | Varespladib met… COVID-19 Coronavirus Inf… Severe Acute Re… Syndrome Coronavirus Dis… Disease Caused … | Part 2 of the study was paused on 03-May-2022 due to slow enrollment following low infection
rates and hospitalizations of patients with severe COVID-19, and did not recommence prior to
study closure (early termination) on 22-Nov-2022. - | |||
| NCT04782245 2020-005713-40 Details | 2023-08-07 Interventional | 2 | 0 | Dapagliflozin Heart Failure End-stage Heart… | New recommandations - | |||
| NCT04680962 Details | 2023-08-07 Interventional | 3 | 0 | Rituximab Arthritis Arthritis, Rheu… Rheumatoid Arth… | Study closed for business reasons before patient recruitment was initiated. - | |||
| NCT04644315 Details | 2023-08-07 Interventional | 2 | 1 | Alectinib Brain Neoplasms Bronchial Neopl… Carcinoma, Bron… Cholangiocarcin… Colonic Disease… Colorectal Neop… Digestive Syste… Digestive Syste… Gastrointestina… Gastrointestina… Head and Neck N… Intestinal Dise… Intestinal Neop… Lymphoma, Large… Melanoma Neoplasms Neoplasms by Si… Neuroendocrine … Ovarian Neoplas… Pancreatic Neop… Respiratory Tra… Respiratory Tra… Salivary Gland … Sarcoma Thoracic Neopla… Thyroid Cancer,… Thyroid Disease… Thyroid Neoplas… Central Nervous… | The data from this study is no longer needed. - | |||
| NCT04544995 2020-002359-39 Details | 2023-08-07 Interventional | 1 | - | Dostarlimab Niraparib Neoplasms | The study was paused for enrolment to further assess clinical data - | |||
| NCT03788694 Details | 2023-08-07 Interventional | 1 | 0 | Ketamine Suicidal Ideati… | Study was never funded nor started, no participants were enrolled - | |||
| NCT04972968 2021-000648-23 Details | 2023-08-04 Interventional | 2 | 181 | Glucocorticoids Giant Cell Arte… Polymyalgia Rhe… | Business Decision - | |||
| NCT03926143 2019-000061-20 Details | 2023-08-04 Interventional | 2 | 9 | Anetumab ravtan… Maytansine Tubulin Modulat… Neoplasms Solid Tumors | Due to strategic company decisions, the development of anetumab ravtansine was stopped. Due to the small sample size and heterogeneous population, survival distributions and the extent of long-term survival in the applicable populations cannot be reliably estimated from the study results. Overall results were reported. Pooling was done because there is only a single patient treated with combination and no summary tables on a single patient. | |||
| NCT02774291 Details | 2023-08-04 Interventional | 1 | 3 | Aldesleukin Cyclophosphamid… Fludarabine Fludarabine pho… Interleukin-2 Lenograstim Neoplasms Neoplasms, Seco… HLA-A2 Positive… Metastatic Mali… Metastatic Mali… | Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and
Study Completion Dates have been revised based accordingly based on respective definitions - | |||
| NCT02689024 2015-003650-40 Details | 2023-08-04 Interventional | 4 | 239 | Acetaminophen Bupivacaine Diclofenac Dipyrone Fentanyl Ibuprofen Levobupivacaine Morphine Naproxen Ropivacaine Delirium Hip Fractures Anesthesia | recruitment too slow; intervention was standard care in patients who were not included; acute
care pathways changed due to policy regarding hip fracture patients - |